Generating Next-Generation Antibody-Nanoparticle Conjugates through the Oriented Installation of Non-Engineered Antibody Fragments

Published in: Chemical Science

Document Version: Peer reviewed version

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
Copyright 2017 the authors.
This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the author guidelines.

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal’s standard Terms & Conditions and the ethical guidelines, outlined in our author and reviewer resource centre, still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.
Generating Next-Generation Antibody-Nanoparticle Conjugates through the Oriented Installation of Non-Engineered Antibody Fragments

Michelle K. Greene¹, Daniel A. Richards², João C. F. Nogueira², Katrina Campbell³, Peter Smyth¹, Marcos Fernández², Christopher J. Scott¹,*, Vijay Chudasama²,4,*

¹ Centre for Cancer Research and Cell Biology, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, Belfast, UK; ² Department of Chemistry, University College London, London, UK; ³ Institute for Global Food Security, School of Biological Sciences, Queen’s University Belfast, Belfast, UK; ⁴ Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal

* These authors contributed equally to this article

E-mails: c.scott@qub.ac.uk; v.chudasama@ucl.ac.uk

E-mail: c.scott@qub.ac.uk; v.chudasama@ucl.ac.uk
Abstract

The successful development of targeted nanotherapeutics is contingent upon the conjugation of therapeutic nanoparticles to target-specific ligands, with particular emphasis being placed on antibody-based ligands. Thus, new methods that enable the covalent and precise installation of targeting antibodies to nanoparticle surfaces are greatly desired, especially those which do not rely on costly and time-consuming antibody engineering techniques. Herein we present a novel method for the highly controlled and oriented covalent conjugation of non-engineered antibody F(ab) fragments to PLGA-PEG nanoparticles using disulfide-selective pyridazinedione linkers and strain-promoted alkyne-azide click chemistry. Exemplification of this method with trastuzumab and cetuximab showed significant improvements in both conjugation efficiency and antigen binding capability, when compared to commonly employed strategies for antibody-nanoparticle construction. This new approach paves the way for the development of antibody-targeted nanomedicines with improved paratope availability, reproducibility and uniformity to enhance both biological activity and ease of manufacture.

Introduction

The application of nanoparticles as drug delivery vehicles has attracted significant interest owing to potential benefits of such platforms, such as improved pharmacokinetic and safety profiles of encapsulated cargo. Several nanoformulations are now marketed, whilst numerous others are under clinical evaluation.¹,² Many nanoformulations are developed for oncology applications in particular.³ Nanoparticles can ‘passively’ accumulate within tumours by exploiting defects in neovascular endothelial junctions and impaired lymphatic drainage; a phenomenon known as the enhanced permeability and retention (EPR) effect. However, surface functionalisation of nanoparticles with targeting ligands has the potential to significantly enhance cellular uptake and retention at the tumour site in a concept referred to as ‘active’ targeting.⁴-⁶

A variety of ligands have been explored for such purposes, including aptamers, peptides and carbohydrates, although antibodies are perhaps the most frequently employed.⁷-¹⁰ Numerous bioconjugation methods exist to graft these ligands to the surface of nanoparticles, with common approaches including carbodiimide and maleimide chemistries.¹¹,¹² Carbodiimide coupling involves the derivatisation of a carboxyl group with cross-linking agents such as 1-ethyl-3-([3-dimethylaminopropyl] carbodiimide (EDC), followed by their direct conjugation to amines resulting in the generation of an amide bond. Depending on the direction of the conjugation, antibodies can be coupled to nanoparticles by virtue of free amine or carboxyl functionalities on lysine or aspartic/glutamic acid residues, respectively. However, this approach is encumbered by low reaction efficiencies and generates highly heterogeneous nanoconjugates, where optimal orientation and
functionality of paratopes cannot be guaranteed due to the high abundance of reactive amine- and carboxyl-containing residues throughout antibodies. Alternatively, maleimide chemistry can in theory facilitate site-specific conjugation to cysteine residues liberated by the reduction of the inter-strand disulfide bonds of antibodies.\textsuperscript{12-14} However, multiple reports have questioned the cysteine selectivity of maleimide conjugation under commonly employed conditions,\textsuperscript{15,16} the resultant bioconjugate would bear a thioether bond that has been shown to be inherently unstable \textit{in vivo},\textsuperscript{17-19} and such a strategy results in the loss of a covalent link between antibody chains. Nonetheless, reports throughout the literature demonstrate the advantages of utilising other site-specific chemistries for the generation of nanoconjugates, including improved antigen binding and greater product homogeneity.\textsuperscript{9,12,20,21} Many of these approaches involve the installation of site-selective amino acid residues using site-directed mutagenesis, followed by subsequent pairing with an appropriate reactive group on the nanoparticle surface.\textsuperscript{9,14,22,23,24,25,26} Whilst this approach allows for the oriented presentation of antibody ligands, it is restricted by the need for time consuming and expensive antibody engineering.

Given these challenges, novel strategies are required to refine antibody conjugation to nanoparticles, with emphasis on: (i) optimising the presentation of the antibody for maximal interaction with cognate targets; and (ii) improving the homogeneity and efficiency of conjugation of antibodies in their native state to aid manufacturability. Previously, we described a novel approach for the functional re-bridging of native inter-strand disulfide bonds of full antibodies and their constituent fragments, \textit{i.e.} resulting in no loss of covalent linkage between antibody chains and modifying at positions that are distal from the antibody binding site.\textsuperscript{27-33} This involved the selective insertion of pyridazinedione moieties bearing reactive handles into reduced disulfide bonds, thus enabling site-specific incorporation of ‘click’ domains without impinging upon antibody functionality. Here we describe the application of this disulfide re-bridging technology to site-selectively modify trastuzumab (TRAZ) F(ab) to bear a strained alkyne handle distal to the paratope and conjugate it to azide-functionalised nanoparticles. This novel approach is compared to conventional methods in order to determine the importance of chemical strategy on the performance of nanoconjugates (Figure 1). We demonstrate superior binding to HER2 of nanoconjugates formed by our new method versus NHS ester conjugation, highlighting the potential of this approach to overcome the shortcomings of conventional coupling chemistries employed in many targeted nanoformulations to date.
**Results and discussion**

Our study began with the synthesis of a novel heterobifunctional linker that would facilitate conjugation to an antibody disulfide at one end and attachment to a nanoparticle at the other. For attachment to the nanoparticle surface, we decided to incorporate the strained alkyne BCN due to its ability to engage in copper free strained-promoted alkyl-azole cycloaddition (SPAAC) reactions and our confidence in being able to formulate azide-functionalised nanoparticles (discussed in detail below). Despite wide-spread use within biomedical research, SPAAC has remained largely unexplored for the generation of nanoconjugates and we took this opportunity to appraise it in this light. To impart site-selective protein reactivity to the linker, the BCN moiety was linked to a dibromopyridazinedione, chosen for its exquisite disulfide reactive selectivity and the excellent stability profile of antibody conjugates formed thereof. Synthesis of the strained alkyne functionalised pyridazinedione 3 proceeded from readily available starting materials in a facile manner over three steps (Scheme 1, further details on the synthetic methods can be found in S1-S5 in the ESI).
Scheme 1. Synthesis of strained alkyne functionalised pyridazinedione 3. Reagents and conditions: (i) Dibromomaleic acid, AcOH, reflux, 24 h; (ii) PyBOP, DIPEA, CH₂Cl₂, 21 °C, 16 h.

![Scheme 1](image)

Figure 2. Modification of TRAZ F(ab) with strained alkyne functionalised pyridazinedione 3. A) Scheme 2: Reagents and conditions: (i) 3, TCEP.HCl, BBS pH = 8.0 (2 mM EDTA), 4 °C, 15 h; (ii) Alexafluor®-488-N₃ BBS pH = 8.0 (2 mM EDTA). B) LCMS data showing native 4, conjugated 5, and clicked TRAZ F(ab) 6. Spectra have been annotated for clarity, see Fig(s) S7, S9 and S12 in the ESI for full spectral data.

The monoclonal antibody TRAZ was chosen as a targeting ligand due to its clinical relevance as an approved therapeutic against HER2+ breast cancers. The choice to utilise the F(ab) domain of TRAZ as the targeting component was driven primarily by the growing volume of evidence suggesting antibody fragments provide multiple benefits to the overall performance of nanoconjugates when compared to full antibodies; F(ab)s retain the binding component of a full antibody. Additionally, the use of the F(ab) domain is ideal in that it...
only contains a single solvent accessible disulfide bond to ensure homogeneous modification and that there is only a single site from which the antibody ligand can be attached to the nanoparticle. Furthermore, F(ab) domains can be readily expressed and/or obtained from native full antibody scaffolds via simple enzymatic digestion procedures. In this particular case, we obtained TRAZ F(ab) from native TRAZ via enzymatic digestion (pepsin followed by papain, further details provided in the ESI). Site-selective modification of TRAZ F(ab) with strained alkyne-pyridazinedione 3 was achieved according to previously reported protocols31 (Figure 2A) and confirmed using LCMS (Figure 2B and S9), and SDS-PAGE showed no aggregation or fragmentation (Figure S8) (hereafter referred to as modified TRAZ F(ab) [disulfide] 5). A test click reaction with Alexafluor-488-azide confirmed the presence of the strained alkyne (Figure(s) S10 and S11). As an appropriate control to determine the overall effect of the site-directed chemistry, a strained alkyne was incorporated into TRAZ F(ab) using non-site-selective lysine-NHS chemistry (modified TRAZ F(ab) [lys]) (Figure(s) S13 and S14). Additionally, the F(ab) fragment of cetuximab (CTX) was site-selectively modified to provide a control for antigen target specificity (modified CTX F(ab) [disulfide]) (Figure(s) S17 and S18). CTX was considered a suitable targeting ligand control in this context, given that it does not engage HER2 but rather binds to EGFR, another member of the ErbB family of receptor tyrosine kinases.35

Following preparation of the various F(ab) domains, we next explored the potential for site-specific functionalisation of nanoparticles with modified TRAZ F(ab) [disulfide] 5. To facilitate ‘click’ conjugation to this antibody fragment, a novel PLGA nanoparticle incorporating a complementary azide moiety was developed. A single emulsion solvent evaporation approach was employed to generate a homogeneous population of azide-terminated nanoparticles from a 25%:75% polymer blend of PLGA-PEG-azide and PLGA RG502H (nude azide NP) (Table 1). These nanoparticles were subjected to stability assessment over several months, with no significant change in physicochemical characteristics observed upon storage at 4 °C or -20 °C (Figure S19). Conjugation of modified TRAZ F(ab) [disulfide] 5 to azide-functionalised nanoparticles was then enabled by incubating both components for 2 h under ambient conditions, yielding a nanoconjugate with a protein loading of 193.1 ± 49.9 pmoles/mg polymer (modified TRAZ F(ab) NP [disulfide]) (Table 1). Contrary to our approach, similar reports of the ‘click’ functionalisation of nanoparticles via alkyne-azide cycloaddition most often involve copper catalysis, which can impart toxicities that ultimately limit the biomedical application of the nanoconjugate.36-40 A range of equimolar controls were also formulated in parallel, which included: (i) native TRAZ F(ab) 4 conjugated to NHS-functionalised nanoparticles (native TRAZ F(ab) NP), (ii) modified TRAZ F(ab) [lys] conjugated to azide-functionalised nanoparticles, with the linker chemistry being introduced at lysine residues as opposed to reduced disulfides (modified TRAZ F(ab) NP [lys]), (iii) native CTX F(ab) conjugated to NHS-functionalised nanoparticles (native CTX F(ab) NP) and (iv) modified CTX F(ab) [disulfide] conjugated to azide-functionalised nanoparticles (modified CTX F(ab) NP [disulfide]) (Table
1) Quantification of F(ab) content within these nanoformulations revealed that conjugation via the strained alkyne proceeded with much greater efficiency compared to NHS ester chemistry (Table 1). These findings are consistent with the enhanced reaction kinetics of SPAAC click chemistry over NHS ester chemistry and also the improved stability of the surface bound azide when compared to the activated carboxylic acid. Further characterisation experiments included ESEM imaging, which revealed the spherical morphology and uniform size distribution of selected nanoformulations, with similar diameters to those acquired via dynamic light scattering (DLS) in Table 1 (Figure 3).

### Table 1. Characterisation of nanoformulations.

<table>
<thead>
<tr>
<th>Nanoformulation</th>
<th>Polymer</th>
<th>Diameter (nm)</th>
<th>PDI*</th>
<th>Zeta potential (mV)*</th>
<th>F(ab) conjugated (pmols/mg polymer)±</th>
<th>Conjugation efficiency (%)±</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nude NHS NP</td>
<td>PLGA-PEG-NHS</td>
<td>191.1 ± 1.2</td>
<td>0.16 ± 0.01</td>
<td>-4.6 ± 0.6</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Native TRAZ F(ab) NP</td>
<td>PLGA-PEG-NHS</td>
<td>210.4 ± 2.7</td>
<td>0.18 ± 0.01</td>
<td>-3.5 ± 0.1</td>
<td>65.3 ± 24.0</td>
<td>6.2 ± 2.3</td>
</tr>
<tr>
<td>Native CTX F(ab) NP</td>
<td>PLGA-PEG-NHS</td>
<td>191.2 ± 1.8</td>
<td>0.11 ± 0.01</td>
<td>-3.9 ± 0.4</td>
<td>103.8 ± 29.1</td>
<td>9.9 ± 2.8</td>
</tr>
<tr>
<td>Nude azide NP</td>
<td>PLGA-PEG-azole</td>
<td>187.4 ± 1.8</td>
<td>0.02 ± 0.01</td>
<td>-2.7 ± 0.6</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Modified TRAZ F(ab) NP [disulfide]</td>
<td>PLGA-PEG-azole</td>
<td>192.4 ± 1.5</td>
<td>0.05 ± 0.02</td>
<td>-1.9 ± 0.7</td>
<td>193.1 ± 49.9</td>
<td>18.4 ± 4.7</td>
</tr>
<tr>
<td>Modified TRAZ F(ab) NP [lys]</td>
<td>PLGA-PEG-azole</td>
<td>207.4 ± 0.1</td>
<td>0.13 ± 0.02</td>
<td>-3.1 ± 0.3</td>
<td>475.0 ± 221.7</td>
<td>45.2 ± 21.1</td>
</tr>
<tr>
<td>Modified CTX F(ab) NP [disulfide]</td>
<td>PLGA-PEG-azole</td>
<td>189.9 ± 0.2</td>
<td>0.05 ± 0.01</td>
<td>-2.3 ± 0.1</td>
<td>208.4 ± 86.5</td>
<td>19.8 ± 8.2</td>
</tr>
</tbody>
</table>

* Data expressed as mean ± SD  
+ Equimolar amounts of each F(ab) domain were initially added to the nanoparticle conjugation reaction

**Figure 3.** ESEM imaging of nanoformulations. (A) Modified TRAZ F(ab) NP [disulfide] and (B) native TRAZ F(ab) NP were dried on double-sided copper tape mounted onto aluminium stubs, sputter-coated with gold and imaged with an ESEM. Scale bar = 4 μm.
Having successfully developed modified TRAZ F(ab) NP [disulfide], we next explored the ability of the nanoconjugate to bind to the HER2 target receptor. Initial studies employed surface plasmon resonance (SPR) to examine binding activity towards a HER2 fusion protein immobilised on a carboxymethylated dextran chip. Although binding of native TRAZ F(ab) NP was detected via SPR, an equivalent polymer concentration of modified TRAZ F(ab) NP [disulfide] showed a significantly enhanced binding profile (Figure 4A). No appreciable binding of nude NP (both NHS and azide) or CTX F(ab) NP (both native and modified) controls was observed, confirming the dependence of the interaction on TRAZ F(ab). Moreover, HER2 binding of modified TRAZ F(ab) NP [lys] was also negligible despite highly efficient coupling of the fragment to nanoparticles (see Table 1), indicating that this conjugation approach restricted paratope accessibility. This comparison demonstrates that the site-selective nature of pyridazinedione conjugation to F(ab) plays a critical role in the observed improvements in antigen binding; indicating improved paratope accessibility granted by the oriented display of the fragments on the nanoparticle surface.

**Figure 4. Enhanced binding of modified TRAZ F(ab) NP [disulfide] to HER2 versus native TRAZ F(ab) NP.** (A) HER2 binding activity of native TRAZ F(ab) NP, modified TRAZ F(ab) NP [disulfide] and associated controls (10 mg polymer/mL) was assessed by SPR. (B) HER2 binding activity of rhodamine 6G-loaded native TRAZ F(ab) NP, modified TRAZ F(ab) NP [disulfide] and associated controls (200 µg polymer/mL) was assessed by modified ELISA. Data expressed as mean ± SEM. Statistical significance was established by one-way ANOVA and Tukey’s post-hoc test (****p≤0.0001).
To exclude the possibility that enhanced binding of modified TRAZ F(ab) NP [disulfide] is a consequence of free F(ab) complexation rather than direct coupling to nanoparticles, we also analysed HER2 binding capacity by modified ELISA. Rhodamine 6G was encapsulated within the various nanoformulations to enable a fluorescent readout of binding to immobilised HER2 fusion protein. These studies produced similar trends to earlier SPR analyses, demonstrating superior binding to HER2 of modified TRAZ F(ab) NP [disulfide] versus native TRAZ F(ab) NP and associated controls (Figure 4B). Consistent with our findings, direct comparisons of carbodiimide and click chemistry-based approaches for nanoparticle functionalisation have also been described in the literature with a similar enhancement in targeting efficiency conferred by the latter.41-45 Several of these reports employ full antibodies as targeting ligands whereas our approach offers a distinct advantage through the use of F(ab) fragments comprising a sole disulfide bond. This ensures that the click-reactive handle is exclusively installed at a single site located distal from the paratope.

The HER2 targeting specificity of modified TRAZ F(ab) NP [disulfide] and native TRAZ F(ab) NP was next validated via modified ELISA, where pre-incubation of HER2-coated wells with an excess of TRAZ full antibody significantly impeded nanoparticle binding (Figure 5Ai and 5Aii). These findings were further bolstered by competition modified ELISA formats, where simultaneous addition of TRAZ full antibody and modified TRAZ F(ab) NP [disulfide] to HER2-coated wells inhibited nanoparticle binding in a concentration-dependent manner (Figure 5B). Collectively, these results demonstrate the successful coupling of TRAZ F(ab) domains to NHS- and azide-functionalised nanoparticles by distinct approaches, generating active nanoconjugates with retained binding capacity for the cognate HER2 antigen.
Figure 5. HER2 targeting specificity of TRAZ F(ab) NP. (A) HER2 binding activity of (i) native TRAZ F(ab) NP, (ii) modified TRAZ F(ab) NP [disulfide] and associated controls (200 µg polymer/mL) was assessed by modified ELISA ± pre-block with TRAZ full antibody (20 µg/mL). (B) HER2 binding activity of modified TRAZ F(ab) NP [disulfide] (200 µg polymer/mL) was assessed by modified ELISA in competition with TRAZ full antibody (0.000051–20 µg/mL). Data expressed as mean ± SEM. Statistical significance was established by one-way ANOVA and Tukey’s post-hoc test (****p≤0.0001).
We next examined the basis for the enhanced HER2 binding activity of the nanoconjugate generated using the site-selective chemistry, modified TRAZ F(ab) NP [disulfide]. To assess whether this effect was simply attributed to enhanced F(ab) loading on the nanoconjugate rather than optimised paratope orientation, we formulated both native TRAZ F(ab) NP and modified TRAZ F(ab) NP [disulfide] using various input amounts of the antibody fragments, ranging from approximately 210 to 2100 pmoles per mg polymer. Higher loadings of modified TRAZ F(ab) [disulfide] 5 on azide-functionalised nanoparticles were observed, with stepwise increases in coupling that correlated with the initial amount of F(ab) added, highlighting the unique degree of control afforded by this conjugation approach (Figure 6A). As before, enhanced binding of modified TRAZ F(ab) NP [disulfide] was observed upon SPR analysis, even when the F(ab) loading was almost half that of native TRAZ F(ab) NP (Figure 6A, nanoformulations 5 and 8). This suggests that significant benefits can be achieved even in the case of lower F(ab) loadings, establishing the positive effect of using more controlled (enabling orientation) chemistries. Intriguingly, this data also revealed that HER2 binding activity diminished with higher loadings of modified TRAZ F(ab) [disulfide] 5 on nanoparticles, suggestive of potential steric hindrance effects leading to suboptimal paratope display. Using fluorescently labelled nanoparticles, these studies were replicated via modified ELISA, with comparable findings to SPR analyses (Figure 6B).
Figure 6. Enhanced binding of modified TRAZ F(ab) NP [disulfide] is not attributed to improved protein conjugation. (A) HER2 binding activity of native TRAZ F(ab) NP or modified TRAZ F(ab) NP [disulfide] (10 mg polymer/mL) with various protein loadings was assessed by SPR. Representative sensorgram shown, with corresponding details for numbered samples in the below table. (B) HER2 binding activity of native TRAZ F(ab) NP or modified TRAZ F(ab) NP [disulfide] (400 µg polymer/mL) with various protein loadings was assessed by modified ELISA. Protein loadings are expressed as pmoles of F(ab) per mg polymer. Data expressed as mean ± SEM.

Binding of modified TRAZ F(ab) NP [disulfide] to HER2 was then evaluated in a more biologically relevant context using cell-based assays. The nanoconjugate was fluorescently labelled via encapsulation of nile red and incubated with the HER2-positive HCC1954 breast cancer line (Figure S20), with confocal microscopy demonstrating a clear association of modified TRAZ F(ab) NP [disulfide] with these cells (Figure 7A). Co-incubation with an excess
of TRAZ full antibody markedly ablated fluorescent labeling of the cells, indicating that the binding of the modified TRAZ F(ab) NP [disulfide] was HER2-dependent.

**Figure 7. Validation of TRAZ F(ab) functionality in cell-based assays.** (A) Confocal microscopy images of HCC1954 cells treated with modified TRAZ F(ab) NP [disulfide] encapsulating nile red (400 µg polymer/mL) ± TRAZ full antibody (200 µg/mL) for 18 h. Blue and red staining denote nuclei and nanoparticles, respectively. Scale bar = 25 µm. (B) BT474 cells were treated with (i) native TRAZ F(ab) NP or (ii) modified TRAZ F(ab) NP [disulfide] and associated controls (500 µg polymer/mL). CellTiter-Glo assay was performed at 48, 96 and 144 h following treatment. Data expressed as mean ± SEM.

In a final series of studies, we examined the therapeutic effects of the TRAZ F(ab) nanoconjugates in vitro. These experiments could not be undertaken with the HCC1954 cell line used for confocal analyses, given that it shows limited sensitivity to TRAZ. However, numerous reports have demonstrated that TRAZ full antibody or its constituent fragments can reduce the viability of BT474 breast cancer cells and so this line was deemed an appropriate model following confirmation of HER2 expression (Figure S20).[^46-49] Here, we assessed whether TRAZ F(ab) could induce a similar reduction in viability of BT474 cells...
when presented in a nanoparticle-bound format. Whilst treatment with free native TRAZ F(ab) 4 led to a gradual reduction in cell viability over time as anticipated, this effect was much less pronounced for the corresponding nanoconjugate (Figure 7Bi). However, upon treatment with modified TRAZ F(ab) NP [disulfide], the reduction in cell viability was much more comparable to free modified TRAZ F(ab) [disulfide] 5 (Figure 7Bii). These findings are consistent with enhanced paratope accessibility on modified TRAZ F(ab) NP [disulfide] conferred via the site-specific conjugation approach. Importantly, these studies also confirmed that the installation of a pyridazinedione linker did not adversely affect the functionality of TRAZ F(ab). Previous work by ourselves and others has shown that antibody display on nanoparticle surfaces can enhance receptor cross-linking; thus mimicking ligand interactions to enhance downstream biological effects.8,50,51 However, as HER2 is a ligand-less receptor, it is not surprising that no enhancement of the effect on cell viability was observed with these particular non-drug loaded nanoconjugates.

To conclude, we have described a novel strategy for the site-specific functionalisation of nanoparticles that promotes the uniform and outward projection of paratopes for maximal target interaction. Using TRAZ F(ab) as a model platform, we demonstrate the successful re-bridging of the inter-chain disulfide bond with a heterobifunctional linker and subsequent ‘click’ coupling to nanoparticles bearing complementary azide moieties. The controlled orientation of TRAZ F(ab) afforded by this approach leads to superior binding to HER2 when compared with conventional NHS ester coupling chemistry, with retention of F(ab) functionality in cell-based assays, demonstrating the importance of controlled chemical ligation for nanoconjugate performance. Crucially, these findings also extend to other receptor-ligand pairings including EGFR-cetuximab (Figure S21), highlighting the versatility of this novel approach and how it may be tailored for diverse applications. This work offers a significant contribution to the ongoing endeavor to refine nanoconjugate design, with the aim of generating more controlled, homogeneous systems that can be readily translated.

Acknowledgements

This work was partially funded through a US-Ireland R&D Partnership grant awarded by HSCNI (STL/5010/14), and we gratefully acknowledge the i-sense EPSRC IRC in Early Warning Sensing Systems for Infectious Diseases (EP/K031953/1) for funding DAR.

References

1) C. Anselmo and S. Mitragotri, Bioengineering & Translational Medicine, 2016, 1, 10-29.


Enabling oriented installation of non-engineered antibody fragments on nanoparticle surfaces to create next-generation antibody-nanoparticle conjugates.